AstraZeneca to invest £120 million in factory
AstraZeneca has announced plans to invest £120 million in a new facility at its global manufacturing site in Macclesfield, UK to continue production of cancer drug Zoladex.
The investment secures 300 existing jobs at the site and will create over 200 temporary jobs during the construction and commissioning phase between now and early 2017.
Zoladex has been manufactured at AstraZeneca's Macclesfield plant for more than 25 years.
David Smith, executive vice-president, operations at AstraZeneca, said: "This new facility will support the continued production of this important medicine in the UK.
"Having considered a number of options globally, we believe it is the right choice to build the new facility in Macclesfield, which has been home to Zoladex manufacturing - and the expertise that goes along with it - for many years.
"This investment is a further signal of our long term commitment to the UK, and to the North West."
